ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead will buy Corus Pharma ...

July 24, 2006 | APPEARED IN VOLUME 84, ISSUE 30

Gilead Sciences intends to exercise its option to acquire Corus Pharma for $365 million. Gilead invested $25 million in Corus in April, becoming the firm's second largest shareholder and gaining the option to buy the rest of the company. Other investors in Corus, which is developing respiratory and infectious disease products, include several investment banks.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment